NasdaqGS:EXELBiotechs
CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations
Exelixis reported new phase 3 CABINET trial data for CABOMETYX in advanced neuroendocrine tumors.
The subgroup analysis showed significant improvements in progression free survival regardless of tumor functional status.
These data were presented at ASCO 2026 and expand the evidence base for CABOMETYX in neuroendocrine tumors.
For investors following NasdaqGS:EXEL, the CABINET subgroup results arrive with the stock at $52.7 and strong recent returns, including 20.9% year to date and 22.5%...